

*The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CK Life Sciences Int'l. (Holdings) Inc.**

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8222)

## **DISCLOSURE PURSUANT TO RULE 17.20 OF THE GEM LISTING RULES**

The Board wishes to announce the following information in accordance with Rule 17.20 of the GEM Listing Rules.

In compliance with Rule 17.20 of the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"), the board of directors (the "Board") of CK Life Sciences Int'l. (Holdings) Inc. (the "Company") announces that, on 29th July, 2008, the Company together with Ecofertiliser Pty Ltd ("Ecofertiliser"), Apil Healthcare Int'l Pty Ltd ("Apil"), Lipa Pharmaceuticals Limited ("Lipa"), Isnecca Pty Limited ("Isnecca") and Accensi Pty Ltd ("Accensi"), all being indirect wholly-owned subsidiaries of the Company, as guarantors and Ample Castle Limited ("Ample"), an indirect wholly-owned subsidiary of the Company, as borrower entered into a facility agreement (the "Agreement") with Commonwealth Bank of Australia, Singapore Branch ("CBA Singapore"), as lender.

Pursuant to the Agreement, CBA Singapore will grant a 3-year term loan of US\$121 million ("Facility") to Ample for the sole purpose of refinancing the existing loans made available to Ecofertiliser, Apil, Lipa, Isnecca and Accensi by Commonwealth Bank of Australia.

As one of the conditions mentioned in the Agreement, Cheung Kong (Holdings) Limited (being the controlling shareholder of the Company currently holding approximately 44.30% of the entire issued share capital of the Company) has provided a confirmation that as at 26th July, 2008, it held not less than 44.01% interest in the Company.

Subject to the terms and conditions of the Agreement, any loan made under the Facility shall be repaid three years after the date on which the relevant loan is to be made.

Disclosure will be included in the quarterly, half-year and annual reports of the Company for so long as the obligation continues to exist.

By Order of the Board  
**CK Life Sciences Int'l., (Holdings) Inc.**  
**Eirene Yeung**  
*Company Secretary*

Hong Kong, 29th July, 2008

*As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Chu Kee Hung; and the Non-executive Directors are Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director), Mrs. Kwok Eva Lee (Independent Non-executive Director) and Mr. Colin Stevens Russel (Independent Non-executive Director).*

*This announcement, for which the Directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and is not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the "Latest Company Announcements" page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of its posting and on the website of the Company at [www.ck-lifesciences.com](http://www.ck-lifesciences.com).*